Literature DB >> 18456723

Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation.

Markéta Bébarová1, Tom O'Hara, Jan L M C Geelen, Roselie J Jongbloed, Carl Timmermans, Yvonne H Arens, Luz-Maria Rodriguez, Yoram Rudy, Paul G A Volders.   

Abstract

Two mechanisms are generally proposed to explain right precordial ST-segment elevation in Brugada syndrome: 1) right ventricular (RV) subepicardial action potential shortening and/or loss of dome causing transmural dispersion of repolarization; and 2) RV conduction delay. Here we report novel mechanistic insights into ST-segment elevation associated with a Na(+) current (I(Na)) loss-of-function mutation from studies in a Dutch kindred with the COOH-terminal SCN5A variant p.Phe2004Leu. The proband, a man, experienced syncope at age 22 yr and had coved-type ST-segment elevations in ECG leads V1 and V2 and negative T waves in V2. Peak and persistent mutant I(Na) were significantly decreased. I(Na) closed-state inactivation was increased, slow inactivation accelerated, and recovery from inactivation delayed. Computer-simulated I(Na)-dependent excitation was decremental from endo- to epicardium at cycle length 1,000 ms, not at cycle length 300 ms. Propagation was discontinuous across the midmyocardial to epicardial transition region, exhibiting a long local delay due to phase 0 block. Beyond this region, axial excitatory current was provided by phase 2 (dome) of the M-cell action potentials and depended on L-type Ca(2+) current ("phase 2 conduction"). These results explain right precordial ST-segment elevation on the basis of RV transmural gradients of membrane potentials during early repolarization caused by discontinuous conduction. The late slow-upstroke action potentials at the subepicardium produce T-wave inversion in the computed ECG waveform, in line with the clinical ECG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456723      PMCID: PMC2494753          DOI: 10.1152/ajpheart.91495.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  46 in total

1.  Role of the C-terminal domain in inactivation of brain and cardiac sodium channels.

Authors:  M Mantegazza; F H Yu; W A Catterall; T Scheuer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Secondary structure of the human cardiac Na+ channel C terminus: evidence for a role of helical structures in modulation of channel inactivation.

Authors:  Joseph W Cormier; Ilaria Rivolta; Michihiro Tateyama; An-Suei Yang; Robert S Kass
Journal:  J Biol Chem       Date:  2001-12-10       Impact factor: 5.157

3.  Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism.

Authors:  Colleen E Clancy; Yoram Rudy
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

4.  Late potentials and the Brugada syndrome.

Authors:  Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2002-06-19       Impact factor: 24.094

5.  Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients.

Authors:  Jeroen P P Smits; Lars Eckardt; Vincent Probst; Connie R Bezzina; Jean Jacques Schott; Carol Ann Remme; Wilhelm Haverkamp; Günter Breithardt; Denis Escande; Eric Schulze-Bahr; Hervé LeMarec; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

6.  Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes.

Authors:  G Baroudi; M Chahine
Journal:  FEBS Lett       Date:  2000-12-29       Impact factor: 4.124

7.  Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome.

Authors:  Matteo Vatta; Robert Dumaine; George Varghese; Todd A Richard; Wataru Shimizu; Naohiko Aihara; Koonlawee Nademanee; Ramon Brugada; Josep Brugada; Gumpanart Veerakul; Hua Li; Neil E Bowles; Pedro Brugada; Charles Antzelevitch; Jeffrey A Towbin
Journal:  Hum Mol Genet       Date:  2002-02-01       Impact factor: 6.150

8.  Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes.

Authors:  I Rivolta; H Abriel; M Tateyama; H Liu; M Memmi; P Vardas; C Napolitano; S G Priori; R S Kass
Journal:  J Biol Chem       Date:  2001-06-15       Impact factor: 5.157

9.  Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family.

Authors:  F Kyndt; V Probst; F Potet; S Demolombe; J C Chevallier; I Baro; J P Moisan; P Boisseau; J J Schott; D Escande; H Le Marec
Journal:  Circulation       Date:  2001-12-18       Impact factor: 29.690

10.  Ionic current basis of electrocardiographic waveforms: a model study.

Authors:  Kazutaka Gima; Yoram Rudy
Journal:  Circ Res       Date:  2002-05-03       Impact factor: 17.367

View more
  15 in total

1.  Cardiac electrophysiological substrate underlying the ECG phenotype and electrogram abnormalities in Brugada syndrome patients.

Authors:  Junjie Zhang; Frédéric Sacher; Kurt Hoffmayer; Thomas O'Hara; Maria Strom; Phillip Cuculich; Jennifer Silva; Daniel Cooper; Mitchell Faddis; Mélèze Hocini; Michel Haïssaguerre; Melvin Scheinman; Yoram Rudy
Journal:  Circulation       Date:  2015-03-25       Impact factor: 29.690

Review 2.  Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing.

Authors:  John R Giudicessi; Dan M Roden; Arthur A M Wilde; Michael J Ackerman
Journal:  Circulation       Date:  2018-02-06       Impact factor: 29.690

3.  Using computational modeling to predict arrhythmogenesis and antiarrhythmic therapy.

Authors:  Jonathan D Moreno; Colleen E Clancy
Journal:  Drug Discov Today Dis Models       Date:  2009

4.  The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization.

Authors:  Arthur A M Wilde; Pieter G Postema; José M Di Diego; Sami Viskin; Hiroshi Morita; Jeffrey M Fish; Charles Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2010-07-24       Impact factor: 5.000

Review 5.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org).

Authors:  Pieter G Postema; Christian Wolpert; Ahmad S Amin; Vincent Probst; Martin Borggrefe; Dan M Roden; Silvia G Priori; Hanno L Tan; Masayasu Hiraoka; Josep Brugada; Arthur A M Wilde
Journal:  Heart Rhythm       Date:  2009-07-08       Impact factor: 6.343

Review 6.  Computational approaches to understand cardiac electrophysiology and arrhythmias.

Authors:  Byron N Roberts; Pei-Chi Yang; Steven B Behrens; Jonathan D Moreno; Colleen E Clancy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-10       Impact factor: 4.733

7.  Brugada syndrome risk loci seem protective against atrial fibrillation.

Authors:  Laura Andreasen; Jonas B Nielsen; Stine Darkner; Ingrid E Christophersen; Javad Jabbari; Lena Refsgaard; Jens J Thiis; Ahmad Sajadieh; Arnljot Tveit; Stig Haunsø; Jesper H Svendsen; Nicole Schmitt; Morten S Olesen
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

8.  Challenging cardiac electrophysiology.

Authors:  Ruben Coronel
Journal:  Front Physiol       Date:  2010-05-28       Impact factor: 4.566

9.  The cardiac sodium channel displays differential distribution in the conduction system and transmural heterogeneity in the murine ventricular myocardium.

Authors:  C A Remme; A O Verkerk; W M H Hoogaars; W T J Aanhaanen; B P Scicluna; C Annink; M J B van den Hoff; A A M Wilde; T A B van Veen; M W Veldkamp; J M T de Bakker; V M Christoffels; C R Bezzina
Journal:  Basic Res Cardiol       Date:  2009-03-03       Impact factor: 17.165

10.  Basis for the Induction of Tissue-Level Phase-2 Reentry as a Repolarization Disorder in the Brugada Syndrome.

Authors:  Alfonso Bueno-Orovio; Elizabeth M Cherry; Steven J Evans; Flavio H Fenton
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.